Dr. Ameet P. Patel, MD
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Medical school
- University of Florida College of Medicine (2016)
- Years since graduation
- 10
- In the NPI registry since
- 2016
- Medicare patients seen, 2024
- 298
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2016Medical school: University of Florida College of Medicine
- 2016Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
FL license ME172728 -
Hematology (Internal Medicine) Physician
FL license ME172728
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Akron General Medical Center Akron, OH
- St Anthonys Hospital Saint Petersburg, FL
- Orlando Health Bayfront Hospital Saint Petersburg, FL
- HCA Florida St Petersburg Hospital Saint Petersburg, FL
- HCA Florida Northside Hospital Saint Petersburg, FL
Medical groups
- Florida Cancer Specialists and Research Institute, LLC (498 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 298
- Services billed
- 37,676
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram | 10,680 | 13 |
| Injection, daratumumab, 10 mg and hyaluronidase-fihj | 6,841 | 11 |
| Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | 3,970 | 32 |
| Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 2,860 | 16 |
| Injection, decitabine, 1 mg | 2,500 | 11 |
| Injection, dexamethasone sodium phosphate, 1 mg | 2,072 | 48 |
| Injection, granisetron hydrochloride, 100 mcg | 1,860 | 24 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 1,030 | 195 |
| Established patient office or other outpatient visit, 30-39 minutes | 749 | 171 |
| Blood test, comprehensive group of blood chemicals | 679 | 157 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Acyclovir Other prescribers in St Petersburg, FL | 77 |
| Valacyclovir (valacyclovir hcl) Other prescribers in St Petersburg, FL | 52 |
| Ninlaro (ixazomib citrate) | 43 |
| Eliquis (apixaban) Other prescribers in St Petersburg, FL | 41 |
| Warfarin Sodium Other prescribers in St Petersburg, FL | 39 |
| Gabapentin Other prescribers in St Petersburg, FL | 33 |
| Revlimid (lenalidomide) | 32 |
| Dexamethasone Other prescribers in St Petersburg, FL | 31 |
| Fluconazole Other prescribers in St Petersburg, FL | 29 |
| Penicillin V Potassium Other prescribers in St Petersburg, FL | 27 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 39 companies reported 85 payments worth $11,879 in total to this clinician.
| AstraZeneca UK Limited | $4,020 |
|---|---|
| Legend Biotech USA Inc. | $3,526 |
| Pfizer Inc. | $2,319 |
| AbbVie Inc. | $166 |
| Genzyme Corporation | $147 |
| Adaptive Biotechnologies Corporation | $145 |
| AstraZeneca Pharmaceuticals LP | $141 |
| Novartis Pharmaceuticals Corporation | $135 |
| Consulting Fee | $9,184 |
|---|---|
| Food and Beverage | $2,660 |
| Education | $35.06 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Legend Biotech USA Inc. Dec 18, 2025 | Consulting Fee CARVYKTI · Oncology | $3,064 |
| AstraZeneca UK Limited Oct 9, 2025 | Consulting Fee | $2,680 |
| Pfizer Inc. Dec 17, 2025 | Consulting Fee ELREXFIO · ONCOLOGY | $2,100 |
| AstraZeneca UK Limited Oct 29, 2025 | Consulting Fee | $1,340 |
| AstraZeneca Pharmaceuticals LP Nov 19, 2025 | Education IMFINZI · Oncology · in-kind Company’s descriptionJournal Article | $35.06 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 1 companies. The companies reported $24,411 in research payments for these studies, mostly to the institutions running them.
- M23-362 - A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
AbbVie Inc. - A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma
AbbVie Inc. · Active, not recruiting · NCT05451810 - A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.